CYP3A4 and stroke disorder: The concomitant use of P-gp/CYP3A4 inhibitors was associated with a higher bleeding risk (aHR 1.24, 95% CI, 1.18–1.30) and higher all-cause mortality (aHR 1.07, 95% CI, 1.02–1.11), while the use of P-gp/CYP3A4 inducers was associated with a higher risk to develop stroke (aHR 1.31, 95% CI, 1.03–1.68).